Form 4: Keros Therapeutics Director Tomer Kariv Boosts Stake with New Equity Awards

Keros Therapeutics, Inc. Director and 10% owner Tomer Kariv has acquired 5,250 restricted stock units and 10,500 stock options, aligning his interests further with shareholders.

Summary

• Tomer Kariv, a Director and 10% Owner of Keros Therapeutics, Inc. (KROS), acquired 5,250 shares of Common Stock in the form of a Restricted Stock Unit (RSU) award on June 4, 2025.
• The RSU award vests fully on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Mr. Kariv also acquired 10,500 stock options on June 4, 2025, with an exercise price of $14.82 per share.
• These stock options vest in equal quarterly installments over 12 months following the grant date, and will be fully vested by the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Following these transactions, Mr. Kariv directly beneficially owns 5,250 shares of Common Stock and 10,500 stock options.
• Additionally, Mr. Kariv indirectly beneficially owns 2,284,612 shares through Israel IV, 1,121,045 shares through Cayman IV, and 1,226,412 shares through China IV, totaling 4,632,069 indirect shares, where he may be deemed to share voting and investment power as a Managing Partner of Pontifax Management 4 G.P. (2015) Ltd., the ultimate general partner of these entities.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the equity awards align the director's interests with shareholders, which is generally viewed favorably, though it's a routine compensation event.

Positives

• The acquisition of restricted stock units and stock options by a director and 10% owner demonstrates increased alignment of management's interests with those of shareholders.
• Equity awards are a common form of compensation that incentivizes long-term performance and value creation.

Future Outlook

The document primarily details past transactions and vesting schedules for equity awards, indicating a future alignment of interests through continued service.

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity, specifically the grant of equity compensation to a director and significant shareholder. Such grants are common practice in the biotechnology and pharmaceutical industries to attract and retain key talent and align their incentives with company performance.

Related Party Transactions

• Disclosure of indirect beneficial ownership of 4,632,069 shares through Israel IV, Cayman IV, and China IV, where the reporting person, as a Managing Partner of Pontifax Management 4 G.P. (2015) Ltd., may be deemed to share voting and investment power. The reporting person disclaims beneficial ownership of these shares except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting all employees, the compensation structure for leadership can set a precedent for broader employee incentive programs.

Next Steps

• The Restricted Stock Units (RSUs) are scheduled to fully vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• The stock options will vest in equal quarterly installments over the 12 months following the grant date, fully vesting by the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Keros Therapeutics, KROS, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Beneficial Ownership, Director, 10% Owner, Equity Compensation